Septerna (SEPN) Non-Current Deffered Revenue (2025 - 2026)
Septerna (SEPN) recorded quarterly Non-Current Deffered Revenue of $92.2 million in Q1 2026, down 12.97% quarter-over-quarter from $105.9 million in Q4 2025.
Septerna (SEPN) Non-Current Deffered Revenue (2025 - 2026) Analysis & Trends
Septerna's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $92.2 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $92.2 million; the TTM figure through Mar 2026 stood at $92.2 million (changed N/A YoY), while the FY2025 annual figure was $105.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $92.2 million for Q1 2026 at Septerna, down from $105.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $120.6 million in Q3 2025 to a low of $92.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | 92.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.18 Mn |
| Dec 31, 2025 | 105.92 Mn |
| Sep 30, 2025 | 120.65 Mn |